Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Double-Blind, Adaptive Randomized Trial of Antenatal MMSPlus Versus UNIMAPP MMS and Postnatal MMSPlus Versus UNIMAPP MMS or IFA to Improve Infant Birth Outcomes and Growth at 6 Months

NCT07029282 is registered in ClinicalTrials.gov with Aga Khan University as lead sponsor.

NCT NCT07029282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07029282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Double-Blind, Adaptive Randomized Trial of Antenatal MMSPlus Versus UNIMAPP MMS and Postnatal MMSPlus Versus UNIMAPP MMS or IFA to Improve Infant Birth Outcomes and Growth at 6 Months
Lead sponsor
Aga Khan University
Phase
Phase 3
Overall status
Recruiting
Start date
July 8, 2025
Completion date
December 31, 2027
Enrollment
3,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adaptive trial, multiple micronutrient deficiencies during pregnancy, neurodevelopment outcome, newborn health, nutrition during pregnancy, postnatal growth